PALO ALTO, Calif.--(BUSINESS WIRE)--Anacor Pharmaceuticals, Inc. (NASDAQ:ANAC) today announced its financial results for the quarter ended March 31, 2015.
“We continue to work with our partner Sandoz to optimize the commercial opportunity for KERYDIN® and believe, based on the continued growth in prescriptions, that we are making good progress,” said Paul L. Berns, Chairman and Chief Executive Officer of Anacor.
Help employers find you! Check out all the jobs and post your resume.
